Compare Manulife Financial Corporation (MFC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Sana Biotechnology Inc — how do they compare? Manulife Financial Corporation trades at $42.81 (market cap $69.96B), while Sana Biotechnology Inc trades at $3.18 (market cap $873.84M). The key difference: Manulife Financial Corporation is far larger — about 80.1× Sana Biotechnology Inc's market cap, and Manulife Financial Corporation pays a 3.14% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MFC | SANA | |
|---|---|---|
Market Cap | $69.96B | $873.84M |
Sector | Financials | Health |
52-Week High | $43.39 | $5.92 |
52-Week Low | $29.90 | $2.68 |
Enterprise Value | $66.52B | $848.03M |
Dividend Yield | 3.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $42.56, down 1.91% today but remains near 52-week highs. The stock shows strong fundamentals with revenue growth from $46.2B in 2024 to $53.0B in 2025 and consistent profitability (12.07% net margin). Technical indicators are mixed with bullish moving averages but overbought RSI levels. Recent Q1 2026 earnings missed expectations despite strong Asia performance, while analyst consensus remains bullish with 57% buy ratings.
MFC presents a compelling value case with reasonable valuation (P/E 17.75) and dividend yield support. Key opportunities include AI integration partnerships and Asia growth, though risks include wealth management outflows and regulatory scrutiny. The stock's current technical overbought condition suggests potential near-term consolidation before resuming upward trajectory.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
